Portal de Periódicos da CAPES

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

2019; Elsevier BV; Volume: 14; Issue: 7 Linguagem: Inglês

10.1016/j.jtho.2019.03.020

1556-1380

Sebastian Michels, Bartomeu Massutí, Hans‐Ulrich Schildhaus, Jeremy Franklin, Martin Sebastian, Enriqueta Felip, Christian Grohé, Delvys Rodríguez‐Abreu, Diana S.Y. Abdulla, Helge Bischoff, Christian Brandts, Enric Carcereny, J. Corral, Anne‐Marie C. Dingemans, Eva Pereira, Jana Fassunke, Rieke Fischer, Masyar Gardizi, Lukas C. Heukamp, Amelia Insa, Anna Kron, Roopika Menon, Thorsten Persigehl, Martin Reck, Richard Riedel, Rebecca Roth, Andreas H. Scheel, Matthias Scheffler, Petra Schmalz, Egbert F. Smit, Meike Limburg, Mariano Provencio, Niki Karachaliou, Sabine Merkelbach‐Bruse, Martin Hellmich, Lucia Nogová, Reinhard Büttner, Rafael Rosell, Jürgen Wolf,

Pancreatic and Hepatic Oncology Research

IntroductionROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and East Asia. Here we present data on efficacy and safety of a prospective phase II trial evaluating crizotinib in European ROS1-positive patients (EUCROSS).Patients and MethodsThe trial was a multicenter, single-arm phase II trial (Clinicaltrial.gov identifier: NCT02183870). Key eligibility criteria included patients who were 18 years of age or older with advanced/metastatic lung cancer and centrally confirmed ROS1-rearranged lung cancer (fluorescence-in situ hybridization). Treatment included 250 mg crizotinib twice daily. The primary endpoint was investigator-assessed objective response rate (ORR) (Response Evaluation Criteria in Solid Tumors, version 1.1). Key secondary endpoints were progression-free survival (PFS), overall survival, efficacy by independent radiologic review, safety, health-related quality of life, and molecular characterization of tumor tissue.ResultsThirty-four patients received treatment. Four patients were excluded from efficacy analysis. Investigator ORR was 70% (95% confidence interval [CI]: 51–85; 21 of 30 patients) and median PFS was 20.0 months (95% CI: 10.1–not reached). Two patients with ROS1 wild-type sequences assessed by DNA sequencing had progression as best response. CD74-ROS1-positive patients had a trend towards a higher ORR and longer median PFS. TP53-co-mutant patients had a significantly shorter median PFS than wild-type patients (7.0 months, 95% CI: 1.7–20.0 versus 24.1 months, 95% CI: 10.1–not reached; p = 0.022). Treatment-related adverse events were documented in 33 of 34 patients (97%).ConclusionsCrizotinib is highly effective and safe in patients with ROS1-rearranged lung cancer. ROS1-/TP53-co-aberrant patients had a significantly worse outcome compared to TP53 wild-type patients.